Overview

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Status:
Active, not recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

Phase:

Phase 2

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborators:

AstraZeneca
Daiichi Sankyo Co., Ltd.

Treatments:

Ado-trastuzumab emtansine